Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) announced that on January 1, 2026 it awarded inducement grants to two new employees under its 2024 Inducement Plan.

The grants are time-based restricted stock units totaling 22,800 shares of common stock, with one-third vesting annually over three years and vesting subject to continued service. The 2024 Inducement Plan was adopted by the board in June 2024. The awards were approved by Intellia’s compensation committee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Key Figures

Inducement RSUs granted 22,800 shares Aggregate RSUs for two new employees under 2024 Inducement Plan

RSU vesting period 3 years One-third of RSUs vest annually over three years

Nasdaq rule cited Listing Rule 5635(c)(4) Basis for inducement grants outside stockholder-approved plans

Inducement Plan year 2024 Inducement Plan Plan adopted by board in June 2024

Current share price $8.99 Price before publication of inducement grant news

52-week trading range $5.90–$28.25 Positioned closer to 52-week low than high pre-news

Market capitalization $1,041,311,035 Equity value prior to this HR-related announcement

Market Reality Check

$9.21 Last Close

Volume Volume 3,013,622 is below the 20-day average of 3,407,776, indicating no pre-news volume spike. normal

Technical Shares at $8.99 are trading below the $11.32 200-day moving average and well under the $28.25 52-week high.

Peers on Argus

Peers showed mixed moves: DNTH and RCUS were up, ELVN and ZYME were down, and TRML was flat, suggesting stock-specific rather than broad sector trading.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 05	Inducement grants	Neutral	-1.8%	Small inducement RSU awards for new hires under 2024 Inducement Plan.
Nov 10	Clinical data update	Positive	+2.2%	Longer-term Phase 1 ATTR cardiomyopathy data showing durable TTR reduction and benefits.
Nov 08	Clinical data update	Positive	+2.2%	Positive pooled Phase 1/2 HAE data with high attack-free and LTP-free rates.
Nov 06	Earnings & pipeline	Negative	-9.2%	Q3 results alongside disclosure of FDA clinical hold and significant net loss.
Oct 27	Safety event update	Negative	-42.2%	Pause in MAGNITUDE trials after Grade 4 liver transaminase elevations and bilirubin rise.

Pattern Detected

Price reactions have generally aligned with news tone: positive clinical updates saw gains, while safety issues and financial updates with a clinical hold drove notable declines.

Recent Company History

Over recent months, Intellia has balanced significant clinical progress with safety and regulatory challenges. Positive Phase 1 and pooled Phase 1/2 data for nexiguran ziclumeran and lonvoguran ziclumeran in ATTR and HAE supported modest gains of about 2.21% on Nov 8–10, 2025. However, a safety event and subsequent FDA clinical hold on MAGNITUDE trials in late October led to sharp declines of -42.23% and -9.21%. Administrative items like prior inducement grants on Dec 1, 2025 saw only a small -1.77% move, indicating limited market impact from such HR-related awards.

Market Pulse Summary

This announcement details routine inducement equity awards totaling 22,800 RSUs for two new employees under the 2024 Inducement Plan, granted in line with Nasdaq Listing Rule 5635(c)(4). These grants are time-based, vesting over 3 years, and sit outside stockholder-approved plans. In context, recent history has been driven more by clinical data and the MAGNITUDE trial hold than by HR-related equity actions. Investors may watch future clinical, regulatory, and financial updates for more material catalysts.

Key Terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”) for..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"time-based restricted stock units (“RSUs”) for an aggregate of 22,800 shares..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

equity incentive plans financial

"awards were granted outside of Intellia’s stockholder-approved equity incentive plans..."

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

nasdaq listing rule 5635(c)(4) regulatory

"approved ... as a material inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2026, it awarded inducement grants to two new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 22,800 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

Intellia Contacts:

Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com

Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com

FAQ

What did Intellia (NTLA) announce on January 2, 2026 about employee inducement grants?

Intellia announced it awarded time-based RSU inducement grants to two new employees totaling 22,800 shares, granted on January 1, 2026.

How do the Intellia (NTLA) RSUs vest and what are the service conditions?

The RSUs vest one-third annually over three years and are conditioned on the employee’s continued service through each vesting date.

Under which plan were Intellia (NTLA) inducement awards granted and when was it adopted?

The awards were granted under Intellia’s 2024 Inducement Plan, which the board adopted in June 2024.

Why were Intellia (NTLA) inducement grants approved under Nasdaq Listing Rule 5635(c)(4)?

The compensation committee approved the awards as a material inducement to employment, which is the allowance provided by Nasdaq Listing Rule 5635(c)(4).

Do Intellia (NTLA) inducement RSUs come from shareholder-approved equity plans?

No; the awards were granted outside Intellia’s stockholder-approved equity incentive plans pursuant to the 2024 Inducement Plan.